Multi-omics analysis of primary aldosteronism

Multi-omics Studies of Primary Aldosteronism

This study will test whether multi-omics profiling of people with primary aldosteronism, people with primary hypertension, and healthy volunteers can find biological markers that improve diagnosis and subtyping.

Quick facts

• Study type: Observational
• Enrollment: 400 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Peking University First Hospital (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT07111351 on ClinicalTrials.gov

What this trial studies

Researchers will collect clinical data and biological samples from adults with primary aldosteronism, adults with primary hypertension, and age- and sex-matched healthy controls to perform integrated multi-omics analyses (for example genomics, transcriptomics, proteomics, and metabolomics). Clinical information will include diagnostic measures such as aldosterone-to-renin ratios, confirmatory testing results, and subtype differentiation data when available. The project aims to link molecular signatures with clinical phenotypes to identify biomarkers that could simplify diagnosis and clarify whether a patient has unilateral or bilateral disease. Data will be generated and analyzed at Peking University First Hospital with comparison across the three participant groups.

Who should consider this trial

Good fit: Adults aged 18–80 with a diagnosis of primary aldosteronism or primary hypertension, or age- and sex-matched healthy volunteers with complete medical records who can give informed consent are ideal candidates.

Not a fit: People with prior adrenal-region chemotherapy or radiotherapy, active HIV/hepatitis B/C infection, known malignancy or autoimmune disease, or those who withdraw consent are excluded and may not receive benefit.

Why it matters

Potential benefit: If successful, this could lead to earlier and more accurate diagnosis and more personalized treatment choices for people with primary aldosteronism.

How similar studies have performed: Prior genomic and transcriptomic work in primary aldosteronism has identified driver mutations and molecular signatures, but fully integrated multi-omics approaches are still emerging and not yet widely established.

Eligibility criteria

Inclusion Criteria:

1. Diagnosed with primary aldosteronism , primary hypertension , or age- and sex-matched healthy controls;
2. Aged 18-80 years with complete medical records;
3. Willing to participate voluntarily and provide informed consent.

Exclusion Criteria:

1. History of chemotherapy or radiotherapy in the adrenal region ;
2. Positive serological or nucleic acid test results for HIV, hepatitis B, or hepatitis C , or a prior confirmed diagnosis;
3. Individuals with malignancies or autoimmune disorders ;
4. Study withdrawal during the trial period

Where this trial is running

Beijing, Beijing Municipality

• Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Wencong Han

Conditions Primary Aldosteronism